Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

J Grarup, C Rappoport, N W Engen, C Carey, F Hudson, E Denning, S Sharma, E Florence, M J Vjecha, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group, J Grarup, C Rappoport, N W Engen, C Carey, F Hudson, E Denning, S Sharma, E Florence, M J Vjecha, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group

Abstract

Objectives: The aim of this report is to describe the challenges, successes and patterns of enrolment in the Strategic Timing of AntiRetroviral Treatment (START) study.

Methods: START is a collaboration of many partners with central coordination provided by the protocol team, the statistical and data management centre (SDMC), the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) network leadership, international coordinating centres and site coordinating centres. The SDMC prepared reports on study accrual, baseline characteristics and site performance that allowed monitoring of enrolment and data quality and helped to ensure the successful enrolment of this large international trial. We describe the pattern of enrolment and challenges faced during the enrolment period of the trial.

Results: An initial pilot phase began in April 2009 and established feasibility of accrual at 101 sites. In August 2010, funding approval for an expanded definitive phase led to the successful accrual of 4688 participants from 215 sites in 35 countries by December 2013. Challenges to accrual included regulatory delays (e.g. national/local ethics approval and drug importation approval) and logistical obstacles (e.g. execution of contracts with pharmaceutical companies, setting up of a central drug repository and translation of participant materials). The personal engagement of investigators, strong central study coordination, and frequent and transparent communication with site investigators, community members and participants were key contributing factors to this success.

Conclusions: Accrual into START was completed in a timely fashion despite multiple challenges. This success was attributable to the efforts of site investigators committed to maintaining study equipoise, transparent and responsive study coordination, and community involvement in problem-solving.

Trial registration: ClinicalTrials.gov NCT00867048.

Keywords: HIV/AIDS; START trial; antiretroviral therapy initiation; enrolment.

© 2015 British HIV Association.

Figures

Figure 1
Figure 1
Operational structure of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) network and Strategic Timing of AntiRetroviral Treatment (START) study governance. SDMC, statistical and data management centre; ICC, international coordinating centre. *Both the Sydney ICC and the Washington ICC have sites in South Africa.
Figure 2
Figure 2
Cumulative quarterly enrolment in the Strategic Timing of AntiRetroviral Treatment (START) trial overall and by region. ART, antiretroviral therapy; CDR, Central Drug Repository; Q, quarter of the year.
Figure 3
Figure 3
Time from finalization of the study protocol to pilot sites opening, after regulatory and network approval.
Figure 4
Figure 4
Days from site opening to first participant enrolled, after regulatory and network approval.

References

    1. Babiker AG, Emery S, Fatkenheuer G et al Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (Suppl 1): S5–S36.
    1. INSIGHT START Study Group . Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1–9.
    1. Geffen N, Aagaard P, Corbelli GM et al Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 10–13.
    1. Neaton JD, Babiker A, Bohnhorst M et al Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials 2010; 7: 705–718.
    1. Cohen MS, Chen YQ, McCauley M et al Prevention of HIV‐1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493–505.
    1. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV‐positive asymptomatic persons. AIDS 2013; 27: 1839–1846.
    1. Collins S. START … and why the time is now. HIV Treat Updat 2010; 197: 3 Available at .
    1. Collins S, Geffen N. Community views: balancing the public health benefits of earlier antiretroviral treatment with the implications for individual patients – perspectives from the community. Curr Opin HIV AIDS 2014; 9: 4–10.
    1. Baker JV, Engen NW, Huppler Hullsiek K et al Assessment of arterial elasticity among HIV‐positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 109–118.
    1. Denning E, Sharma S, Smolskis M et al Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 24–29.
    1. Carr A, Grund B, Neuhaus J et al Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 137–146.
    1. Kunisaki K, Niewoehner DE, Collins G et al Pulmonary function in an international sample of HIV‐positive, treatment‐naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 119–128.
    1. Matthews GV, Neuhaus J, Bhagani S et al Baseline prevalence and predictors of liver fibrosis among HIV‐positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 129–136.
    1. Wright EJ, Grund B, Cysique LA et al Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 97–108.
    1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ et al Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV‐1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14: 281–290.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren